Things
Public call for the selection of project proposals to be financed within the research program of the innovation ecosystem "THE - TUSCANY HEALTH ECOSYSTEM", drawing on the resources of the national plan for recovery and resilience (PNRR), mission 4 " education and research” – component 2 “from research to business” – investment 1.5 – creation and strengthening of “innovation ecosystems for sustainability”, creation of “territorial R&D leaders”, financed by the European Union – EXTGENERATIONEU, issued from Spoke 7 “INNOVATING TRANSLATIONAL MEDICINE”
Who is it aimed at?
The following can request the benefits: − Micro, Small and Medium-sized enterprises (MSMEs), external to the THE Ecosystem, which compete in single or collaborative mode with other enterprises, having the dimensional parameters referred to in Annex I of REG (EC) n . 800/2008 of the Commission of 6 August 2008 (General Block Exemption Regulation) in OJEU L 214 of 9.8.2008; − Large Enterprises (GI), external to the THE Ecosystem, in collaborative mode provided that the requirement of collaboration with at least one MSME; can support a maximum of 70% of the total eligible cost of the project; − research organizations (Od R), external to the THE Ecosystem, in collaborative mode, as defined pursuant to point 1.3 letter (ff) of the new RSI regulation of referred to in communication C(2022) 7388 of 19 October 2022, both public and private.
What does it predict
This announcement intends to support research activities in the following areas:1. Identification of potential targets and/or markers of muscle diseases associated with mutations in the RYR1;2 gene. Optimization of fermentation processes and implementation on pilot plants;3. Development of an industrial technological platform based on artificial intelligence systems for the optimization and production of personalized therapies to be used in the treatment of antibiotic-resistant bacterial infections with a view to precision medicine;4. Production of liposomal delivery systems for innovative hydrophilic and/or lipophilic antimicrobial molecules;5. Development of complex live-like models and animal models of infection;6. Development of tumor animal models, including metastatic models;7. Characterization of the antibody response and antigen-specific memory B cells following vaccination;8. Transcriptomic analysis in mouse models, cell cultures and clinical samples;9. Exploring epigenetic plasticity and tumor heterogeneity in uncommon variants of CLL (ie HCL) and medulloblastoma to pinpoint novel pharmaceutical targets and to characterize new modulators of histone methylation;10. Large-scale peptide synthesis for preclinical drug and medical device development.
